Physician profile
Ryan L Holcomb
NPI 1265832265
$4,849.86
in general payments reported to CMS, 2019-2025
22 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $741 · 2023: $989 · 2024: $1,193 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.96 |
| Education | $245.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $698.00 | 2021-2025 | Opzelura |
| Genzyme Corporation | $653.78 | 2021-2025 | |
| Abbvie INC. | $575.47 | 2021-2025 | |
| Amgen INC. | $550.92 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $466.51 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $277.94 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $253.92 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $219.63 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $205.76 | 2022-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $193.40 | 2021-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $180.13 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $163.81 | 2021-2025 | |
| Krystal Biotech INC | $84.37 | 2024 | Vyjuvek |
| Arcutis Biotherapeutics, INC. | $74.83 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $59.19 | 2023-2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.27 | 2023-2025 | Vtama, Hadlima |
| Smith+Nephew, INC. | $34.26 | 2024-2025 | Collagenase Santyl |
| Galderma Laboratories, L.P. | $29.99 | 2024-2025 | Nemluvio |
| Kyowa Kirin, INC. | $29.45 | 2022 | |
| Sandoz INC. | $23.86 | 2024 | Hyrimoz |
| Pfizer INC. | $15.07 | 2023 | |
| Tactile Systems Technology INC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.